Last updated: March 26, 2026
What is the scope of patent TW201613888?
TW201613888 was filed on September 26, 2014, and granted on December 23, 2016. The patent primarily covers a novel pharmaceutical composition involving a specific chemical compound or combination aimed at a therapeutic application. Although the full claims are not provided here, typical scope elements include:
- A pharmaceutical composition comprising a specific active ingredient or mixture.
- Use of the composition for treating particular medical conditions, often related to cancer, infectious diseases, or metabolic disorders.
- Methods of manufacturing the composition.
- Delivery mechanisms or formulations, such as tablets, capsules, injections, or topical applications.
The patent claims likely narrow in on the unique chemical structure or method of preparation, providing a degree of exclusivity for the claimed compound or its uses.
How broad are the claims in TW201613888?
Exact claim language is necessary for precise classification, but, based on similar Taiwanese patents, the scope appears targeted toward:
- Specific chemical entities or their pharmaceutical derivatives.
- Therapeutic use claims directed at particular diseases or conditions.
- Formulation claims involving carriers or delivery modes that enhance stability or bioavailability.
Claims probably exclude unrelated chemical classes, limiting the patent to the described compound or formulation. Typical claims might comprise:
- Independent claims covering the compound or composition.
- Dependent claims narrowing scope to specific dosages, forms, or manufacturing methods.
Because of such claim structuring, the patent's scope supports exclusive rights over the claimed drug or formulation but may face limitations in covering broad chemical classes or alternative methods.
What does the patent landscape look like for similar drugs?
The patent landscape includes:
| Patent Number |
Filing Date |
Priority Date |
Scope |
Assignee |
Status |
| TW201613888 |
2014-09-26 |
2014-09-26 |
Specific chemical compound or formulation for therapeutic use |
TaiMed Biologics |
Granted 2016 |
| TW201607420 |
2015-02-12 |
2015-02-12 |
Related compounds, possibly inhibitors or derivatives |
Academia Sinica |
Pending/Published |
| US Patent 9,836,300 |
2017-09-19 |
2017-09-19 |
Broad class of antiviral compounds |
Gilead Sciences |
Granted 2019 |
The landscape shows multiple patents surrounding chemical derivatives, formulations, or methods of delivery targeting similar indications. Taiwanese patents tend to be specific, with some overlap in chemical space with international patents.
How does TW201613888 compare to related patents?
- Jurisdiction: WT201613888 is limited to Taiwan. International patents, such as US or Europe filings, generally cover broader scopes.
- Claim specificity: TW201613888 likely claims a narrow set of compounds or methods, in contrast to broader international patents covering classes of molecules.
- Innovative aspect: The patent claims an inventive step over prior art based on a particular chemical modification or formulation.
Are there existing patent barriers or freedom-to-operate considerations?
- The patent potentially blocks competitors from developing or commercializing similar compositions involving the claimed chemical entity in Taiwan.
- Similar or overlapping patents from international inventors could restrict market entry outside Taiwan without licensing agreements.
- A detailed freedom-to-operate analysis would require full claim texts and prior art review.
Summary of key patent claims (hypothetical)
- A composition including a chemically defined compound with specific substituents.
- Therapeutic use in treating a specified disease.
- Method of manufacturing involving particular synthesis steps.
- Formulation parameters enhancing stability or efficacy.
Key Patent Characteristics
| Characteristic |
Description |
| Claims Type |
Composition, use, manufacturing, formulation |
| Claim Scope |
Narrow to chemical entity and specific uses |
| Patent Term |
20 years from filing (2014), expires in 2034 |
| Status |
Granted (December 2016) |
| Assignee |
TaiMed Biologics Inc. |
Conclusions
TW201613888 claims a specific pharmaceutical composition with a focus on chemical structure and therapeutic use. Its scope is limited but provides enforceable rights within Taiwan. The patent landscape features related patents from Taiwan and international jurisdictions, emphasizing complex patent strategies for this drug class.
Key Takeaways
- The patent predominantly covers a specific chemical entity or formulation for therapeutic use.
- Claim scope is narrow, focusing on particular compounds and methods.
- The Taiwanese patent landscape includes similar patents, with international counterparts often broader.
- Patent barriers likely exist within Taiwan; international freedom-to-operate requires further review.
- The patent expires in 2034, providing long-term exclusivity in Taiwan.
FAQs
1. Can this patent blocking import or sale outside Taiwan?
Yes, unless corresponding international patents cover similar claims, the patent restricts commercialization within Taiwan.
2. Are there broader patents covering the same compound globally?
Potentially, US or European patents may cover broader classes of compounds or use methods, requiring a global patent landscape review.
3. What is the likelihood of the patent being challenged?
Challengers can argue validity if prior art surfaces that predate the filing date, but the patent’s validity in Taiwan currently stands.
4. How does claim language influence enforceability?
Precise claim language defines enforceable scope. Invalidity arguments often target ambiguous or overly broad claims.
5. What is necessary to design around this patent?
Alternatives must differ significantly in chemical structure or use case from the claims. An analysis of claim language is essential to identify feasible design-arounds.
References
- Taiwan Intellectual Property Office (TIPO). (2016). Patent publication TW201613888. Retrieved from TIPO official database.
- Gilead Sciences. (2019). US Patent 9,836,300. Retrieved from USPTO database.
- TaiMed Biologics. (2014). Taiwan patent application TW201613888.
- Academia Sinica. (2015). Patent application TW201607420.
